IOVA (Iovance Biotherapeutics, Inc.) Stock Financials & Earnings

IOVAIovance Biotherapeutics, Inc.

Mkt Cap$2B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$264M

Net Income (TTM)-$391M

EPS (TTM)-$1.09

Free Cash Flow (TTM)-$336M

Gross Margin97.2%

Op. Margin-153.1%

Net Margin-148.4%

FCF Margin-127.6%

P/S Ratio (TTM)6.5x

P/E Ratio (TTM)—

YoY Rev Growth+60.6%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$0	-$111M
Q2 23	$238K	-$2M	-$110M
Q3 23	$469K	-$4M	-$118M
Q4 23	$482K	-$4M	-$121M
Q1 24	$715K	-$7M	-$118M
Q2 24	$31M	-$262K	-$102M
Q3 24	$59M	$19M	-$89M
Q4 24	$74M	$28M	-$87M
Q1 25	$49M	-$417K	-$121M
Q2 25	$60M	$3M	-$114M
Q3 25	$67M	$66M	-$95M
Q4 25	$87M	$187M	-$73M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$83M	$28M	—	—
Q2 23	$86M	—	—	$22M
Q3 23	$88M	—	—	$27M
Q4 23	$87M	—	—	$30M
Q1 24	$80M	$8M	$18M	—
Q2 24	$62M	—	—	$34M
Q3 24	$68M	$40M	—	—
Q4 24	$72M	—	—	$43M
Q1 25	$77M	$11M	$33M	—
Q2 25	$79M	—	—	$38M
Q3 25	$75M	—	—	$35M
Q4 25	$69M	—	—	$36M

Revenue by Geography

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$543M	$83M	$626M
Q2 23	$230M	$21M	$251M
Q3 23	$268M	$94M	$361M
Q4 23	$115M	$165M	$280M
Q1 24	$134M	$222M	$356M
Q2 24	$229M	$184M	$413M
Q3 24	$164M	$233M	$397M
Q4 24	$116M	$208M	$324M
Q1 25	$172M	$188M	$360M
Q2 25	$132M	$169M	$301M
Q3 25	$158M	$143M	$301M
Q4 25	$163M	$134M	$297M

Shares Outstanding

Revenue Per Employee

Revenue / Employee